A study detailing the processes that control mole size may help scientists find new ways to prevent skin cancer from growing — ScienceDaily

Moles stop growing when they reach a certain size due to normal interactions between cells, despite having cancer-associated gene mutations, says a new study published today in eLife.

The findings in mice could help scientists develop new ways to prevent skin cancer growth that take advantage of the normal mechanisms that control cell growth in the body.

Mutations that activate the protein made by the BRAF gene are believed to contribute to the development of skin cancer. However, recent studies have shown that these mutations do not often cause skin cancer, but instead result in the formation of completely harmless pigmented moles on the skin. In fact, 90% of moles have these cancer-linked mutations but never go on to form tumours. “Exploring why moles stop growing might lead us to a better understanding of what goes wrong in skin cancer,” says lead author Roland Ruiz-Vega, a postdoctoral researcher at

Read More
Read More

New 3-D model of a DNA-regulating complex in human cells provides cancer clues — ScienceDaily

Scientists have created an unprecedented 3-dimensional structural model of a key molecular “machine” known as the BAF complex, which modifies DNA architecture and is frequently mutated in cancer and some other diseases. The researchers, led by Cigall Kadoch, PhD, of Dana-Farber Cancer Institute, have reported the first 3-D structural “picture” of BAF complexes purified directly from human cells in their native states — rather than artificially synthesized in the laboratory -providing an opportunity to spatially map thousands of cancer-associated mutations to specific locations within the complex.

“A 3-D structural model, or ‘picture,’ of how this complex actually looks inside the nucleus of our cells has remained elusive — until now,” says Kadoch. The newly obtained model represents “the most complete picture of the human BAF complex achieved to date,” said the investigators, reporting in the journal Cell.

These new findings “provide a critical foundation for understanding human disease-associated mutations

Read More
Read More

New England Cancer Specialists will soon offer scalp-cooling technology to help reduce hair loss in cancer patients

By Chiara Battelli MD, President & Lead Physician at New England Cancer Specialists

A cancer diagnosis can change many things about our lives. As patients move forward with their doctor to examine treatment options, one of the major concerns they express is hair loss associated with chemotherapy. Unfortunately, it is hard to predict who will lose their hair even though it is a common and significant side effect of cytotoxic chemotherapy. Studies have shown that hair loss during cancer treatment can lead to lower self-esteem and feelings of depression, ultimately causing up to 10% of patients to forego chemotherapy.

Chemotherapy drugs damage hair follicles in a variety of ways: some drugs cause hair thinning or hair loss only on the scalp, while others can cause hair to thin or fall out on the arms, legs, underarms, eyebrows, or eyelashes. If a person is going to lose hair during treatment, it

Read More
Read More

HIV and lung cancer in East Africa: CWRU and UH secure research funds

Cleveland–Researchers with the Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center (UHCMC) have secured $4 million in funding from the National Institutes of Health (NIH)/National Cancer Institute (NCI) to establish an HIV-associated Malignancy Research Center (HAMRC) focused on lung cancer in East Africa.

The team will collaborate with Ugandan and Tanzanian researchers at the Joint Clinical Research Centre in Kampala, Makerere University Lung Institute, Uganda Cancer Institute, Mulago National Hospital, National Institute for Medical Research (NIMR), Muhumbili National Hospital and the Ocean Road Cancer Institute. The HAMRC will investigate novel approaches to characterize lung cancer epidemiology, somatic mutation burden, HIV and accelerated aging, and radiological features of lung cancer and the relationship to HIV-1 infection.

The focus of this new research center includes establishing national lung cancer diagnostic referral networks in Uganda and Tanzania, teleradiology telepathology, technology transference and training of early career investigators and

Read More
Read More

Researchers identified that SUCLA2-deficient prostate cancer cells can be selectively treated with thymoquinone — ScienceDaily

The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene. Led by researchers at Kanazawa University, the study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted. SUCLA2-deficient prostate cancers represent a significant fraction of those resistant to hormone therapy or metastatic, and a new therapeutic option for this disease would have immense benefits for patients.

Hormone therapy is often chosen for the treatment of metastatic prostate cancer but nearly half of patients develop resistance to the treatment in as little as 2 years. A mutation in RB1, a tumor suppressor gene that keeps cell growth under control, has been pegged as a particularly strong driver of treatment resistance and predicts poor outcome in patients.

“Mutations in tumor suppressor genes are enough to induce initiation and malignant progression of prostate cancer, but

Read More
Read More

New technology allows cancer patients to watch movies during radiation

AURORA, Colo. (KDVR) — No matter the age, radiation treatment can be tough on any cancer patient. Which is why UCHealth helped develop a special piece of technology to help reduce anxiety and stress associated with it.

The technology is called ‘RadFlix’ and it allows patients to safely watch their favorite TV shows and movies all while undergoing radiation.

“This can be a very traumatic experience for these kids,” said Dr. Douglas Holt, the Chief Resident radiation oncologist with the University of Colorado Cancer Center.

Holt helped develop the device. It’s a radiation compatible, video distraction system that can be used with any type of radiation treatment.

“That’s important because it’s very technically challenging to do that in radiation,” Holt said.

Not only is it convenient for a patient to watch TV or a movie on ‘RadFlix’ while undergoing radiation therapy, but it also helps them cut down on the

Read More
Read More

Preliminary results of two large immune therapy studies show promise in advanced cervical cancer — ScienceDaily

Preliminary results from two independent, phase II clinical trials investigating a new PD-1 (programmed cell death protein 1)-based immune therapy for metastatic cervical cancer suggest potential new treatment options for a disease that currently has limited effective options and disproportionately impacts younger women.

David O’Malley, MD, of The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), presented the preliminary study results at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 on Sept. 18. O’Malley was the lead presenter for both trials, which were sponsored by Agenus Inc.

Each study involved more than 150 patients with recurrent or metastatic cervical cancer from cancer treatment centers across the United States and Europe. All patients were previously treated with platinum-based chemotherapy as a first-line therapy. The two independent but consecutive phase II trials tested a new immune-based agent

Read More
Read More

Personalized cancer therapy improves outcomes in advanced disease — ScienceDaily

Patients receiving care for advanced cancer at Moores Cancer Center at UC San Diego Health were more likely to survive or experience a longer period without their disease progressing if they received personalized cancer therapy, report University of California San Diego School of Medicine researchers.

Led by Razelle Kurzrock, MD, director of the Center for Personalized Cancer Therapy at Moores Cancer Center and senior author of the study, a multidisciplinary molecular tumor board was established to advise treating physicians on course of care using an individual patient’s molecular tumor makeup to design precision medicine strategies.

“Patients who underwent a molecular tumor board-recommended therapy were better matched to genomic alterations in their cancer and had improved outcomes,” said Kurzrock. “The three-year survival for patients with the highest degree of matching and who received a personalized cancer therapy was approximately 55 percent compared to 25 percent in patients who received therapy that

Read More
Read More

Cancer cells use nerve-cell tricks to spread from one organ to the next — ScienceDaily

Tumors come in many shapes and forms — curable or deadly, solid or liquid, lodged inside the brain, bone, or other tissues. One thing they all have in common, however, is a knack for molecular deceit. It is often by posing as normal cells, or by hijacking them, that cancer cells advance their takeover of biological systems and learn to grow, survive, and spread to new organs.

Recently, Rockefeller scientists found that breast and lung tumors can appropriate a signaling pathway used by neurons to metastasize. In a report published in Nature, the researchers describe how these cancer cells enlist nearby blood vessels to gain access to this nerve signal, ultimately enabling their escape from the primary tumor and into the bloodstream.

In addition to illuminating previously unseen aspects of tumors’ relationship with their surroundings, the findings could lead to new strategies for diagnostics and treatment.

Blood vessels: more

Read More
Read More

Cancer Biomarkers Market Opportunities, Size, Share, Emerging Trends, Technological Innovation and Forecasts

The MarketWatch News Department was not involved in the creation of this content.

Sep 29, 2020 (AmericaNewsHour) —
Global Cancer Biomarkers Market was valued at USD 13.50 Billion in the year 2017. Global Cancer Biomarkers Market is further estimated to grow at a CAGR of 14% from 2019 to reach USD 37.94 Billion by the year 2025.
The Global Cancer Biomarkers is segmented as by cancer type, by profiling technology, by biomarkers, and by region. On the basis of the type of cancer the Market is segmented as Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer and Others of which breast cancer holds the highest Market share.

On the basis of Profiling Technology, the Global Cancer Biomarkers Market is segmented as OMICS Technology, Imaging Technology, Immunoassays, Cytogenetics, and Bioinformatics of which OMICS Technology is expected to hold the highest Market share in the forecasted period.

Request To Download

Read More
Read More